ROP — Roche Holding AG Share News
0.000.00%
Last trade - 00:00- CH₣254.44bn
- CH₣276.23bn
- CH₣61.52bn
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
Brief: Roche Receives FDA 510(K) Clearance For Cobas® C703 And Cobas® Ise Neo
Brief: Roche Launches The Cobas Mpx-E Assay
Brief: Pharma Mar Receives Positive Opinion From EMA Recommending Approval Of Zepzelca With Atezolizumab
Brief: Roche Launches Cobas Eplex Respiratory Pathogen Panel 3 In CE Markets
Roche halts muscle-disease drug development after trial setback, continues obesity study
Brief: Roche Spokesperson Says Decided To Stop Clinical Development Of Emugrobart For Spinal Muscular Atrophy & Facioscapulohumeral Muscular Dystrophy
Brief: Roche Pursues Muscle Study For Obesity After Halting Other Work - Bloomberg News
Table: Swiss trade surplus at CHF 4.20 bln in February
Reuters Next: Genentech CEO says aiming for tolerable, affordable obesity drug
Reuters Next: Genentech CEO says its flu medicine headed to TrumpRx
Brief: Roche Receives CE Mark For First IVD Immunoassay Blood Test To Identify Carriers Of ApoE4
Europe Research Roundup: Epiroc , Neste , Wacker Chemie
Swiss stocks - Factors to watch on March 12
Swiss stocks - Factors to watch on March 10
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Roche shares drop as oral breast cancer drug fails trial (updated)